Skip to main content

clostridium botulinum neurotoxin type A (Xeomin®)

 

Status: In progress

Symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhea due to neurological/neurodevelopmental disorders

 Draft Recommendation: clostridium botulinum neurotoxin type A (Xeomin) 3986 (PDF, 51Kb)

Medicine details

Medicine name clostridium botulinum neurotoxin type A (Xeomin®)
Formulation 50 units powder for solution for injection, 100 units powder for solution for injection, 200 units powder for solution for injection
Reference number 3986
Indication

As above

Company Merz Pharma UK Ltd
BNF chapter Central nervous system
Submission type Licence extension for paediatric use
Status In progress
AWMSG meeting date 08/12/2021
Date of issue TBC